Xenon Pharma reports FY2023 net loss $182.4M, cash $930.9M; XEN1101 Phase 3 on track

Xenon Pharmaceuticals Inc.

2023-FY EPS reported -$2.73

Net loss of $44.7M in Q4 2023 and $182.4M for FY2023, vs $37.4M and $125.4M in 2022.
R&D expenses $41.1M in Q4, $167.5M for FY2023, driven by XEN1101 Phase 3 epilepsy trials.
Cash and marketable securities $930.9M as of Dec 31, 2023; expected runway into 2027.
X-TOLE2 Phase 3 epilepsy patient enrollment expected to complete late 2024 to early 2025.
End-of-Phase 2 meeting with FDA for XEN1101 in major depressive disorder planned in April 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Xenon Pharmaceuticals Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenon Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-023080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.